Targeted alpha therapy,
delivered with precision.
The RayzeBio Alpha Institute is an educational resource for healthcare professionals exploring the science of targeted alpha therapy and the evolving role of radioligand treatment in cancer care.
A resource built around the questions clinicians are asking
From foundational radiobiology to multidisciplinary care coordination, explore how targeted alpha therapy is reshaping treatment decisions.
The Science of Alpha
How actinium-225 and alpha emitters differ mechanistically from beta-based RLT.
RYZ-101
An investigational Ac-225–based radiopharmaceutical in late-stage development.
Patient Identification
Imaging biomarkers and selection considerations for receptor-targeted therapy.
Multidisciplinary Care
Coordinating oncology, nuclear medicine, and radiology to deliver RLT.
Resources
Webinars, congress data, and downloadable scientific materials.
Pipeline & Trials
ACTION-1, ACTION-2, and ongoing programs across solid tumors.
Pioneering the next wave of radiopharmaceuticals.
RayzeBio, a Bristol Myers Squibb company, is focused on the discovery and development of precision radiopharmaceutical therapies. With an innovation-leading position in actinium-based therapies, we are advancing a pipeline of potentially first-in-class programs.
This Institute exists to support the clinical community as targeted alpha therapy moves from emerging modality to standard of care consideration — with rigorous science, transparent education, and practical guidance for the multidisciplinary team.